This post was originally published on this site
Celltrion Inc.’s shares rallied Monday after the European Commission granted the South Korean biotech firm approval to market its COVID-19 antibody treatment.
The European approval of Regdanvimab, marketed by Celltrion as Regkirona in South Korea, drop up the company’s stock price KR:068270 as much as 18% to 251,000 Korean won ($212.72) after the news was disclosed early Monday.
Shares…
